Company profile
INNOVIVA, INC.
NASDAQ:INVABiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06801223 | phase1 | recruiting | 2026-12-30 | 2028-05-05 | Innoviva Specialty Therapeutics | A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection |
FDA applications (0)
No records yet.